Multiple sclerosis (MS,) is a disease in which the fatty myelin sheaths around the axons of the brain and spinal cord are damaged, leading to demyelination and scarring as well as a broad spectrum of signs and symptoms. Disease onset usually occurs in young adults, and it is more common in females. It has a prevalence that ranges between 2 and 150 per 100,000.
|
[News]
Promising Therapy for Relapsing Multiple Sclerosis
An international team of researchers has found that adding a humanized monoclonal antibody called daclizumab to standard treatment reduces the number of new or enlarged brain lesions in patients with relapsing multiple sclerosis. This new study was published online Feb. 16, 2010, and in the March edition of the Lancet Neurology.
|
|
[News]
MS change With The Seasons
A new US study that compared brain scans of people with multiple sclerosis to weather data over a two year period found that disease activity varied with the seasons, with spring and summer months showing predominantly the highest rates of activity, but with increased temperature and solar activity also showing a strong link. The researchers said designers of drug trials that use brain scans to measure results should also consider the possible influence of seasonal effects.
|
|
[News]
Vascular Multiple Sclerosis Hypothesis and Treatment Questioned
Two important new studies challenge the controversial hypothesis that venous congestion -- chronic cerebrospinal venous insufficiency (CCSVI) -- contributes to the development of multiple sclerosis (MS). This theory has resulted in many MS patients receiving experimental endovascular angioplasty, a treatment for MS unproven by clinical trials.
|
|
[News]
Further Evidence Links Epstein-Barr Virus and Risk of Multiple Sclerosis
Researchers from the Harvard School of Public Health, Walter Reed Army Institute of Research, and a team of collaborators have observed for the first time that the risk of multiple sclerosis (MS) increases by many folds following infection with the Epstein-Barr virus (EBV). This finding implicates EBV as a contributory cause to multiple sclerosis.
|
|
[News]
Statins May Slow Progression of Multiple Sclerosis
A UCSF-led study examining the impact of statins on the progression of multiple sclerosis found a lower incidence of new brain lesions in patients taking the cholesterol-lowering drug in the early stages of the disease as compared to a placebo.
|
|
[News]
Multiple Sclerosis Successfully Treated Yet Again With Adult Stem Cells
After participating in a small clinical trial at Northwestern University, Edwin McClure seems to have recovered from multiple sclerosis (MS). Conducted on 21 participants and led by Dr. Richard Burt, the clinical trial involved treating the MS patients with their own adult stem cells. The only drawback of the study, however, was the use of chemotherapy to destroy each patient's immune system prior to the adult stem cell therapy. Nevertheless, patients such as Mr. McClure have shown dramatic improvement.
|
|
[News]
Gut Bacteria Affect Multiple Sclerosis
Biologists at the California Institute of Technology (Caltech) have demonstrated a connection between multiple sclerosis (MS) -- an autoimmune disorder that affects the brain and spinal cord -- and gut bacteria.
|
|
[Research & Advances]
Men And Women Equally Transmit Genetic Risk Of Multiple Sclerosis To Their
Men and women with multiple sclerosis (MS) equally transmit the genetic risk of the disease to their children, according to a study published June 27, 2007, in the online edition of Neurology®, the medical journal of the American Academy of Neurology. The research contradicts the results of a recent study, which found affected fathers were more likely than affected mothers to transmit the risk of developing MS to their children.
|
|
[Research & Advances]
Multiple Sclerosis Onset: Could Mycobacteria Play a Role?
A non-pathogenic bacterium is capable to trigger an autoimmune disease similar to the multiple sclerosis in the mouse, the model animal which helps to explain how human diseases work. This is what a group of researchers from the Catholic University of Rome, led by Francesco Ria (Institute of General Pathology) and Giovanni Delogu (Institute of Microbiology), have explained for the first time in a recently published article on the Journal of Immunology.
|
|
|
|
|
[
[
[
[